Trial · NCT00939770
Results by group41
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 41
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib | Part A | 280 | mg/m²/dose BID | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID | 6 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A:PF-02341066 130 mg/m²/Dose BID | 7 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A:PF-02341066 165 mg/m²/Dose BID | 23 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A:PF-02341066 215 mg/m²/Dose BID | 11 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A:PF-02341066 280 mg/m²/Dose BID | 38 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID | 11 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID | 14 | Participants | ||
| Number of Participants With Toxicities of Crizotinib | Phase 2:Part C: PF-02341066 280 mg/m2/Dose BID | 10 | Participants | ||
| Steady State C Max of Crizotinib | Dose Level 3 | 294 | Standard Deviation 0 | ng/mL | |
| Steady State C Max of Crizotinib | Dose Level 4 | 601 | Standard Deviation 118 | ng/mL | |
| Steady State C Max of Crizotinib | Dose Level 5 | 717 | Standard Deviation 201 | ng/mL | |
| Steady State C Max of Crizotinib | Dose Level 6 | 972 | Standard Deviation 210 | ng/mL | |
| Steady State C Average of Crizotinib | Dose Level 3 | 246 | Standard Deviation 0 | ng/mL | |
| Steady State C Average of Crizotinib | Dose Level 4 | 469 | Standard Deviation 114 | ng/mL | |
| Steady State C Average of Crizotinib | Dose Level 5 | 582 | Standard Deviation 173 | ng/mL | |
| Steady State C Average of Crizotinib | Dose Level 6 | 731 | Standard Deviation 228 | ng/mL | |
| Steady State AUC of Crizotinib | Dose Level 3 | 2950 | Standard Error 0 | ng•h/mL | |
| Steady State AUC of Crizotinib | Dose Level 4 | 5630 | Standard Error 1370 | ng•h/mL | |
| Steady State AUC of Crizotinib | Dose Level 5 | 6990 | Standard Error 2080 | ng•h/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00939770/results